These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Chemotherapy for ovarian cancer. Lacave AJ; Peláez I; Palacio I N Engl J Med; 1996 May; 334(19):1269-70. PubMed ID: 8606731 [No Abstract] [Full Text] [Related]
4. New therapy for ovarian cancer. Neijt JP N Engl J Med; 1996 Jan; 334(1):50-1. PubMed ID: 7494573 [No Abstract] [Full Text] [Related]
5. Intraperitoneal therapy for advanced ovarian cancer: will it become standard care? Bankhead C J Natl Cancer Inst; 2006 Apr; 98(8):510-2. PubMed ID: 16622116 [No Abstract] [Full Text] [Related]
6. Current status and future directions of platinum/paclitaxel-based chemotherapy of ovarian cancer. Markman M Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-24-S11-27. PubMed ID: 9314295 [TBL] [Abstract][Full Text] [Related]
7. Chemotherapy of advanced ovarian cancer: current status and future directions. Ozols RF; Vermorken JB Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-1-S2-9. PubMed ID: 9045324 [TBL] [Abstract][Full Text] [Related]
8. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409 [TBL] [Abstract][Full Text] [Related]
9. [Advanced cancer of the ovary. The paclitaxel-cisplatin combination as the first-line standard of treatment]. Pecorelli S Recenti Prog Med; 1999 Jun; 90(6):338-41. PubMed ID: 10399475 [No Abstract] [Full Text] [Related]
10. Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study. Bezjak A; Tu D; Bacon M; Osoba D; Zee B; Stuart G; Roy JA; Piccart M; Eisenhauer E J Clin Oncol; 2004 Nov; 22(22):4595-603. PubMed ID: 15466785 [TBL] [Abstract][Full Text] [Related]
11. Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study. McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-13-S2-16. PubMed ID: 9045329 [TBL] [Abstract][Full Text] [Related]
12. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer. Nagourney RA Gynecol Oncol; 2000 Jan; 76(1):143. PubMed ID: 10620464 [No Abstract] [Full Text] [Related]
13. [Paclitaxel (Taxol)--drug of choice in ovarian cancer]. Fishman A Harefuah; 1996 Apr; 130(8):557-60. PubMed ID: 8765885 [No Abstract] [Full Text] [Related]
14. A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer. Kohn EC; Sarosy GA; Davis P; Christian M; Link CE; Ognibene FP; Sindelar WF; Jacob J; Steinberg SM; Premkumar A; Reed E Gynecol Oncol; 1996 Aug; 62(2):181-91. PubMed ID: 8751547 [TBL] [Abstract][Full Text] [Related]
15. Chemotherapy of advanced ovarian cancer. Martoni A; Cacciari N; Angelelli B; Zamagni C; Pannuti F Front Biosci; 1997 Mar; 2():g20-6. PubMed ID: 9159262 [TBL] [Abstract][Full Text] [Related]